NRC Research Associate Programs
Fellowships Office
Policy and Global Affairs

Participating Agencies

  sign inOpen Printer View

RAP opportunity at U.S. Army Medical Research & Materiel Command     AMRMC

Assessment of chemical-induced seizure, neurodegeneration and neuroinflammation: efficacy of medical countermeasures

Location

U.S. Army Medical Research Institute of Chemical Defense, Comparative Medicine Division

opportunity location
97.25.10.B7179 Aberdeen Proving Ground, MD 210105425

Advisers

name email phone
Lucille Ann Lumley lucille.a.lange.civ@health.mil 410.436.1443

Description

Research efforts focus on the characterization of toxicity of organophosphorus nerve agents and other seizure-inducing chemicals, as well as on the identification of improved therapeutics against seizure and seizure-associated brain pathology. In vivo studies are performed in rodents and minipigs using outcome measures of behavior, physiology, biochemistry, and neuroanatomy to evaluate efficacy of candidate pretreatments and therapeutics against chemical-induced toxicity. Classes of anti-seizure medications being evaluated for efficacy against nerve agent exposure include, but are not limited to neurosteroids, antiglutamatergics, anticholinergics administered alone or in combination with benzodiazepines. Neurobehavioral assessments include measures of motor activity and function, cognitive performance, sensorimotor function, emotional memory, and measures of anxiety-like behavior. Telemetry is used to continuously measure electroencephalographic activity (EEG) for identification of seizure and epileptogenesis, as well to measure electrocardiographic activity and alterations in circadian rhythms (body temperature, activity). Histochemistry and stereology are used to evaluate neuropathology and neuroinflammatory responses. In addition, sex and age differences in toxic response to chemical exposure and to medical countermeasure efficacy are evaluated.

References

Lumley L, Niquet J, Marrero-Rosado B, Schultz M, Rossetti F, de Araujo Furtado M, Wasterlain C. Treatment of acetylcholinestearse inhibitor-induced seizures with polytherapy targeting GABA and glutamate receptors. Neuropharmacology 2021; 185:10844. PMID 33359073.

Lumley LA, Du F, Marrero-Rosado B, Stone M, Keith ZM, Schultz C, Whitten K, Walker K, Acon-Chen C, Wright L, Shih TM. Soman-induced toxicity, cholinesterase inhibition and neuropathology in adult male Gottingen minipigs. Toxicology Reports 2021; 8:896-907. PMID: 33996503.

Marrero-Rosado BM, De Araujo M, Kundrick ER, Walker KA, Stone MF, Schultz CR, Nguyen DA, Lumley LA. Ketamine as adjunct to midazolam treatment following soman-induced status epilepticus reduces seizure severity, epileptogenesis, and brain pathology in plasma carboxylesterase knockout mice. Epilepsy & Behavior 2020; 111:107229. PMID 32575012.

 

key words
Chemical warfare nerve agents; Behavior; Seizure; Antiseizure medications; Neuroprotection; Organophosphorus chemicals; neuroinflammation; Toxicology; Animal models; sex differences; epileptogenesis

Eligibility

Citizenship:  Open to U.S. citizens
Level:  Open to Postdoctoral and Senior applicants

Stipend

Base Stipend Travel Allotment Supplementation
$55,000.00 $3,000.00

$6,600 Supplement per year of experience in the DTRA CBD-funded NRC tenure at USAMRICD

Experience Supplement:
Postdoctoral and Senior Associates will receive an appropriately higher stipend based on the number of years of experience past their PhD.

Copyright © 2024. National Academy of Sciences. All rights reserved.Terms of Use and Privacy Policy